Phathom Pharmaceuticals(PHAT)

Focus: Phathom is a public pharmaceutical company focused on novel treatments for gastrointestinal diseases, with commercial revenue concentrated entirely on VOQUEZNA (vonoprazan fumarate) and its combination therapies. The company operates at mid-cap scale (~100–200 employees) with significant R&D intensity.

Gastroenterology Neurology

Profile data last refreshed 7h ago · AI intelligence enriched 1mo ago

Funding Stage

PUBLIC

Employees

51-200

Open Jobs

Should You Work at Phathom Pharmaceuticals?

AI assessment

Phathom offers high-risk, high-reward exposure to a growing GI franchise with substantial cash runway, but single-product dependency and shallow hiring pipeline make it suitable only for specialists seeking focused therapeutic expertise or equity upside.

Why Work Here

Lead product VOQUEZNA generated $55M revenue in FY2025 (vs. $682K in FY2024), demonstrating strong commercial momentum in a validated gastroenterology indication.

Data completeness

7/9 — Strong

Company HealthStrong

Pipeline

Late-stage

3 Phase 3+

LOE Risk

3 in 5yr

VOQUEZNA

Hiring

Stable

Revenue

$55M

Key Products

VOQUEZNA

Gastrointestinal disorders (gastric acid control)

$46K Part D

Growth

Help build intelligence for Phathom Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Deep pipeline of 16 active trials across Phase 1–4, with three Phase 3 programs in GERD, erosive esophagitis, and H. pylori infection offering near-term potential catalysts.

$297M cash position and growing revenue provide stability for R&D-focused roles while company scales commercial operations.

Watch Out For

100% revenue concentration on a single small-molecule platform creates existential business risk if VOQUEZNA faces competitive pressure or adoption challenges post-launch.
Patent cliff on VOQUEZNA in August 2030 (6+ years out) will require pipeline programs to reach maturity or company faces significant restructuring; early-stage programs (8 Phase 1 trials) are immature hedges.
Only 1 active job opening and minimal recent hiring activity signal limited near-term career mobility or growth trajectory within the company.

Generated by Claude from Phathom Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Lead commercial product driving 100% of company revenue; recently launched with demonstrated uptake in Part D prescriptions.

VOQUEZNA DUAL PAK

H. pylori infection

Peak3.9yr

Combination therapy at peak lifecycle stage, expanding label indications beyond monotherapy.

VOQUEZNA

Gastrointestinal disorders (additional indication)

Growth

Additional formulation or indication in growth phase; label expansion opportunity.

VOQUEZNA TRIPLE PAK

H. pylori infection

Peak3.9yr

Triple-therapy combination at peak lifecycle; standard-of-care triple therapy for resistant H. pylori strains.

Pipeline & Clinical Trials

Vonoprazan

Erosive Esophagitis

N/A

Clinical Trials (1)

NCT06660342A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring

N/A

Vonoprazan

Healthy Volunteers

PHASE_1

Clinical Trials (1)

NCT05366738A Study to Determine the Bioavailability of Vonoprazan Sprinkle Capsules on Pudding or on Applesauce Relative to a Vonoprazan Tablet in Healthy Participants

Phase 1

Vonoprazan

Healthy Volunteers

PHASE_1

Clinical Trials (1)

NCT04545944Evaluation of Effect of Vonoprazan on Midazolam Pharmacokinetics in Healthy Participants

Phase 1

Vonoprazan

Healthy Participants

PHASE_1

Clinical Trials (1)

NCT04558216Evaluation of Effect of Rifampin on the Pharmacokinetics of Vonoprazan in Healthy Participants

Phase 1

Vonoprazan

Erosive Esophagitis

PHASE_1

Clinical Trials (1)

NCT06391177A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice Daily

Phase 1

Vonoprazan

Gastroesophageal Reflux Disease

PHASE_1

Clinical Trials (1)

NCT06106022A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux Disease

Phase 1

Vonoprazan

Healthy Participants

PHASE_1

Clinical Trials (1)

NCT04729101Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vonoprazan and Lansoprazole in Healthy Participants

Phase 1

Vonoprazan ODT-1 or ODT-2 without Water

Healthy Volunteers

PHASE_1

Clinical Trials (1)

NCT06831344A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participants

Phase 1

Vonoprazan

Gastroesophageal Reflux

PHASE_1

Clinical Trials (1)

NCT05343364A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan in Adolescents With Symptomatic Gastroesophageal Reflux Disease

Phase 1

Vonoprazan

Non-Erosive Gastro-Esophageal Reflux Disease

PHASE_2

Clinical Trials (1)

NCT04799158A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease

Phase 2

Vonoprazan

Eosinophilic Esophagitis

PHASE_2

Clinical Trials (1)

NCT06851559A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks

Phase 2

Vonoprazan

Non-Erosive Gastro-Esophageal Reflux Disease

PHASE_3

Clinical Trials (2)

NCT05195528A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)

Phase 3

NCT07752407A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks

Vonoprazan

Erosive Esophagitis

PHASE_3

Clinical Trials (1)

NCT04124926Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis

Phase 3

Vonoprazan

Helicobacter Pylori Infection

PHASE_3

Clinical Trials (1)

NCT04167670Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection

Phase 3

PYTEST® 14C-Urea Capsule Breath Test

H. Pylori Infection

PHASE_4

Clinical Trials (1)

NCT07224048Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community-AIM 2

Phase 4

PYTEST® 14C-Urea Breath Test

H Pylori Infection

PHASE_4

Clinical Trials (1)

NCT07224035Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1

Phase 4

Potassium-Competitive Acid Blockers

Barrett Esophagus

Phase 4

Clinical Trials (1)

NCT07788742Efficacy of Potassium-Competitive Acid Blockers in Barrett's Esophagus (PCAB BE Study)

Phase 4

Interview Prep Quick Facts

Portfolio: 4 approved products, 18 clinical trials

Top TAs: Gastroenterology, Oncology

Publications: 26 in PubMed

SEC Filings: 2 available

Open Roles: 1 active job

Portfolio Health

Growth2 (50%)

Peak2 (50%)

4 total products

Therapeutic Area Focus

Gastroenterology

6 pipeline

Oncology

2 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$55M8001%

R&D Spend

$34M(62%)32%

Net Income

-$334M

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Vonoprazan Improves Nocturnal Gastroesophageal Reflux Symptoms in Nonerosive Reflux Disease.

The American journal of gastroenterology

2026

PMID:41081570

Development and Use of a Population Pharmacokinetic Model for Characterizing the Pharmacokinetics of Vonoprazan in Pediatric Patients.

CPT: pharmacometrics & systems pharmacology

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Phathom Pharmaceuticals(PHAT)

Should You Work at Phathom Pharmaceuticals?

Why Work Here

Key Products

Watch Out For

Products & Portfolio (3)

Pipeline & Clinical Trials

Recent News · Phathom Pharmaceuticals(10)

Open Jobs (1)

Intern

Financials (FY2025)

Hiring Trend

Research Publications(10)